A cost-of-illness study of Behçet syndrome in Italy
-
Published:2023-05-22
Issue:
Volume:
Page:
-
ISSN:1618-7598
-
Container-title:The European Journal of Health Economics
-
language:en
-
Short-container-title:Eur J Health Econ
Author:
Lorenzoni ValentinaORCID, Marinello Diana, Palla Ilaria, Mosca Marta, Turchetti Giuseppe, Talarico Rosaria
Abstract
Abstract
Objective
This study aims at evaluating the cost-of-illness (COI) of patients diagnosed with Behcet’s syndrome (BS) in Italy, trying to depict the impact of different costs’ components to the overall economic burden and analysing the variability of costs according to years since diagnosis and age at first symptoms.
Methods
With a cross-sectional evaluation, we surveyed a large sample of BS patients in Italy assessing several dimensions related to BS, also including fact related to the use of health resources utilization, formal and informal care, and productivity losses. Overall costs, direct health, direct non-health, and indirect costs were thus estimated per patient/year considering a Societal perspective and the impact of years since diagnosis, age at first symptoms on costs was evaluated using generalized linear model (GLM) and a two-part model, adjusting for age and distinguishing among employed and non-employed responders.
Results
A total of 207 patients were considered in the present study. From the perspective of the Society, mean overall costs for BS patient were estimated to be 21,624 € (0;193,617) per patient/year. Direct non-health expenses were the main costs component accounting for 58% of the overall costs, followed direct health costs, 36%, while indirect costs because of productivity losses represented 6% of the overall costs. Being employed resulted in significantly lower overall costs (p = 0.006). Results from the multivariate regression analyses suggested that the probability of incurring in overall costs equal to zero decreased as time from BS diagnosis is 1 year or more as compared to newly diagnosed patients (p < 0.001); while among those incurring in expenses, costs decreased for those experiencing first symptoms between 21 and 30 years (p = 0.027) or later (p = 0.032) as compared to those having symptoms earlier. Similar findings emerged among the subgroups of patients declaring themselves as workers, while no impact of years since diagnosis or age of first symptoms was found among non-workers.
Conclusions
The present study offers a comprehensive overview of the economic consequences imposed by BS in a societal perspective, providing insights into the distribution of the different costs component related to BS, thus helping the development of targeted policies.
Funder
Scuola Superiore Sant'Anna
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference28 articles.
1. Nguengang Wakap, S., Lambert, D.M., Olry, A., Rodwell, C., Gueydan, C., Lanneau, V., Murphy, D., Le Cam, Y., Rath, A.: Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020). https://doi.org/10.1038/S41431-019-0508-0 2. García-Pérez, L., Linertová, R., Valcárcel-Nazco, C., Posada, M., Gorostiza, I., Serrano-Aguilar, P.: Cost-of-illness studies in rare diseases: a scoping review. Orphanet J. Rare Dis. (2021). https://doi.org/10.1186/S13023-021-01815-3 3. Posarelli, C., Maglionico, M.N., Talarico, R., Covello, G., Figus, M.: Behçet’s syndrome and ocular involvement: changes over time. Clin. Exp. Rheumatol. 38, 86–93 (2020) 4. Hatemi, G., Seyahi, E., Fresko, I., Talarico, R., Uçar, D., Hamuryudan, V.: One year in review 2021: Behçet’s syndrome. Clin. Exp. Rheumatol. 39(Suppl 132), S3–S13 (2021). https://doi.org/10.55563/CLINEXPRHEUMATOL/LNVC9K 5. Yazici, Y.: Management of Behçet syndrome. Curr. Opin. Rheumatol. 32, 35–40 (2020). https://doi.org/10.1097/BOR.0000000000000666
|
|